Selective compounds can reduce side effects compared to existing therapies.

About

Type II Diabetes and Chronic Inflammation Associated with Vascular Disease Research is on-going into the discovery of agonists to selectively discriminate between the enzymes EPAC1 and EPAC2. Compounds with the required selectivity would have therapeutic benefit in the treatment of inflammation (EPAC1) and type II diabetes (EPAC2). These selective compounds would reduce side effects compared to existing therapies due to the modulation of only the EPAC enzymes. EPAC1 agonists would limit pro-inflammatory cytokine signalling in vascular endothelial cells which would treat chronic inflammation associated with vascular diseases such as atherosclerosis and neo-intimal hyperplasia. EPAC2 agonists would promote insulin secretion from pancreatic beta cells. This would benefit type II diabetes treatment by promoting insulin production, with reduced side effects compared to current therapies. High throughput screening (HTS) assays to screen against EPAC1 and EPAC2 have been developed and validated for hit identification along with a Medium Throughput (TS) screen to discriminate hits between agonists and antagonists.    Key Benefits Selective compounds can reduce side effects compared to existing therapies.   Applications For use in the treatment of inflammation (EPAC1) and type II diabetes (EPAC2).  

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations